A5002841899- Hepatitis C virus research
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Ear and Head Tumors
- Liver Disease Diagnosis and Treatment
- Head and Neck Anomalies
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- Hepatitis B Virus Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Drug-Induced Hepatotoxicity and Protection
University of Toronto
2015-2018
Toronto General Hospital
2018
University Health Network
2017-2018
AbbVie (United States)
2017
Toronto Liver Centre
2015
Shaikh Khalifa Medical City
2012
Mixed cryoglobulinemia is strongly associated with hepatitis C virus (HCV) infection and ranges from being asymptomatic to causing life-threatening vasculitis. In those symptoms, treatment pegylated interferon (pegIFN) ribavirin (RBV) reduces mortality. However, few data are available on the safety efficacy of antiviral therapy direct acting antivirals (DAAs) in HCV-related cryoglobulinemia.Patients treated for DAA±pegIFN were retrospectively evaluated at a tertiary care center. Primary...
Summary Background Guidelines recommend withholding sofosbuvir ( SOF ) in patients with an estimated glomerular filtration rate eGFR of less than 30 mL/min. Aim To assess the risk acute kidney injury AKI no renal contraindications for ‐based treatment. Methods This multicenter retrospective observational study included all consecutive that were treated or telaprevir/boceprevir (TVR/BOC)‐based regimens at two tertiary university centers North America. was defined as increase ≥0.3 mg/ dL...
Mucoepidermoid carcinoma (MEC) of the lung is a rare endobronchial tumor accounting for up to 0.2% primary cancer. We report patient with MEC who presented cough, hemoptysis, and localized findings on chest examination. This case emphasizes importance obtaining adequate biopsy establish correct diagnosis. In addition, it highlights that usually presents in low-grade form, carrying favorable prognosis.
Potent direct-acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection have reduced the need on-treatment monitoring. Currently, response and outcome are determined by HCV RNA testing. A less expensive alternative to verify viral replication is core antigen (HCV Ag). The aim this study was determine if Ag can be used initial confirmation viremia, monitoring determination SVR in patients with receiving DAA treatment. To evaluate role confirming SVR, treated DAAs...